JP2010522182A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010522182A5 JP2010522182A5 JP2009554623A JP2009554623A JP2010522182A5 JP 2010522182 A5 JP2010522182 A5 JP 2010522182A5 JP 2009554623 A JP2009554623 A JP 2009554623A JP 2009554623 A JP2009554623 A JP 2009554623A JP 2010522182 A5 JP2010522182 A5 JP 2010522182A5
- Authority
- JP
- Japan
- Prior art keywords
- halogen
- alkyl
- absent
- hydroxy
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229910052736 halogen Inorganic materials 0.000 claims 61
- 150000002367 halogens Chemical group 0.000 claims 61
- 125000000217 alkyl group Chemical group 0.000 claims 56
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 49
- 125000003118 aryl group Chemical group 0.000 claims 47
- 125000003545 alkoxy group Chemical group 0.000 claims 42
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 26
- 208000002193 Pain Diseases 0.000 claims 25
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 21
- 125000005102 carbonylalkoxy group Chemical group 0.000 claims 17
- 230000001404 mediated effect Effects 0.000 claims 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 14
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 claims 13
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 claims 13
- 125000002947 alkylene group Chemical group 0.000 claims 11
- 125000004043 oxo group Chemical group O=* 0.000 claims 10
- 125000004103 aminoalkyl group Chemical group 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000001118 alkylidene group Chemical group 0.000 claims 7
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 6
- 125000004104 aryloxy group Chemical group 0.000 claims 6
- 125000005242 carbamoyl alkyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 208000014674 injury Diseases 0.000 claims 6
- 201000001119 neuropathy Diseases 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 4
- 208000004078 Snake Bites Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 208000004296 neuralgia Diseases 0.000 claims 4
- 230000007823 neuropathy Effects 0.000 claims 4
- 208000033808 peripheral neuropathy Diseases 0.000 claims 4
- IJXJGQCXFSSHNL-MRVPVSSYSA-N (2s)-2-amino-2-phenylethanol Chemical compound OC[C@@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-MRVPVSSYSA-N 0.000 claims 3
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 3
- RQEUFEKYXDPUSK-ZETCQYMHSA-N (1S)-1-phenylethanamine Chemical compound C[C@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-ZETCQYMHSA-N 0.000 claims 2
- CMTDMIYJXVBUDX-VIFPVBQESA-N (1r)-2-methoxy-1-phenylethanamine Chemical compound COC[C@H](N)C1=CC=CC=C1 CMTDMIYJXVBUDX-VIFPVBQESA-N 0.000 claims 2
- IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 208000010392 Bone Fractures Diseases 0.000 claims 2
- 206010058019 Cancer Pain Diseases 0.000 claims 2
- 206010007882 Cellulitis Diseases 0.000 claims 2
- 208000002881 Colic Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000005171 Dysmenorrhea Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 2
- 208000001640 Fibromyalgia Diseases 0.000 claims 2
- 206010017076 Fracture Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010065390 Inflammatory pain Diseases 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028116 Mucosal inflammation Diseases 0.000 claims 2
- 201000010927 Mucositis Diseases 0.000 claims 2
- 206010029240 Neuritis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010042496 Sunburn Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 239000003556 cannabinoid 2 receptor agonist Substances 0.000 claims 2
- -1 carbamo Le Chemical group 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 201000001352 cholecystitis Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000037805 labour Diseases 0.000 claims 2
- 239000002207 metabolite Substances 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 230000002981 neuropathic effect Effects 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 230000037361 pathway Effects 0.000 claims 2
- 230000002093 peripheral effect Effects 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 208000004371 toothache Diseases 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 claims 1
- XHLPAMPQRZJZPQ-UHFFFAOYSA-N 1-cyclohexyl-4,5,6,7,8,9-hexahydrocycloocta[c]pyrazole-3-carboxylic acid Chemical compound C1=2CCCCCCC=2C(C(=O)O)=NN1C1CCCCC1 XHLPAMPQRZJZPQ-UHFFFAOYSA-N 0.000 claims 1
- 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- JUAASCSVJGFOKG-UHFFFAOYSA-N n-(1-adamantylmethyl)-1-cyclohexyl-4,5,6,7,8,9-hexahydrocycloocta[c]pyrazole-3-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13CNC(=O)C(C=1CCCCCCC=11)=NN1C1CCCCC1 JUAASCSVJGFOKG-UHFFFAOYSA-N 0.000 claims 1
- JCPDFDIHQOALNH-UHFFFAOYSA-N n-(1-adamantylmethyl)-1-cyclopentyl-4,5,6,7,8,9-hexahydrocycloocta[c]pyrazole-3-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13CNC(=O)C(C=1CCCCCCC=11)=NN1C1CCCC1 JCPDFDIHQOALNH-UHFFFAOYSA-N 0.000 claims 1
- TUKOQUXZXVOJHW-UHFFFAOYSA-N n-[1-(1-adamantyl)ethyl]-1-cyclohexyl-4,5,6,7,8,9-hexahydrocycloocta[c]pyrazole-3-carboxamide Chemical compound C1C(C2)CC(C3)CC2CC13C(C)NC(=O)C(C=1CCCCCCC=11)=NN1C1CCCCC1 TUKOQUXZXVOJHW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89601707P | 2007-03-21 | 2007-03-21 | |
| PCT/US2008/055102 WO2008115672A1 (en) | 2007-03-21 | 2008-02-27 | Method for treating cb2 receptor mediated pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010522182A JP2010522182A (ja) | 2010-07-01 |
| JP2010522182A5 true JP2010522182A5 (enExample) | 2011-03-31 |
Family
ID=39766330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009554623A Withdrawn JP2010522182A (ja) | 2007-03-21 | 2008-02-27 | Ｃｂ２受容体介在疼痛を処置する方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2139327A4 (enExample) |
| JP (1) | JP2010522182A (enExample) |
| KR (1) | KR20090120500A (enExample) |
| CN (1) | CN101677555A (enExample) |
| AR (1) | AR065801A1 (enExample) |
| AU (1) | AU2008229265A1 (enExample) |
| CA (1) | CA2681384A1 (enExample) |
| CL (1) | CL2008000817A1 (enExample) |
| MX (1) | MX2009010164A (enExample) |
| PE (1) | PE20090551A1 (enExample) |
| TW (1) | TW200904414A (enExample) |
| UY (1) | UY30974A1 (enExample) |
| WO (1) | WO2008115672A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012090179A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Isoquinoline derivatives as cannabinoid receptor modulators |
| WO2012090177A2 (en) | 2010-12-30 | 2012-07-05 | Lupin Limited | Cannabinoid receptor modulators |
| WO2013005168A2 (en) | 2011-07-05 | 2013-01-10 | Lupin Limited | Cannabinoid receptor modulators |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ548212A (en) * | 2003-12-29 | 2010-07-30 | Sepracor Inc | Pyrrole and pyrazole DAAO inhibitors |
| US7452997B2 (en) * | 2004-03-24 | 2008-11-18 | Janssen Pharmaceutica, N.V. | Tetrahydro-indazole cannabinoid modulators |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| US7825151B2 (en) * | 2005-09-23 | 2010-11-02 | Janssen Pharmaceutica Nv | Hexahydro-cyclooctyl pyrazole cannabinoid modulators |
| UA93389C2 (en) * | 2005-09-23 | 2011-02-10 | Янссен Фармацевтика H.B. | Hexahydro cyclooctyl pyrazole cannabinoid modulators |
-
2008
- 2008-02-27 AU AU2008229265A patent/AU2008229265A1/en not_active Abandoned
- 2008-02-27 CN CN200880016252A patent/CN101677555A/zh active Pending
- 2008-02-27 CA CA002681384A patent/CA2681384A1/en not_active Abandoned
- 2008-02-27 JP JP2009554623A patent/JP2010522182A/ja not_active Withdrawn
- 2008-02-27 KR KR1020097020430A patent/KR20090120500A/ko not_active Withdrawn
- 2008-02-27 WO PCT/US2008/055102 patent/WO2008115672A1/en not_active Ceased
- 2008-02-27 MX MX2009010164A patent/MX2009010164A/es unknown
- 2008-02-27 EP EP08730822A patent/EP2139327A4/en not_active Withdrawn
- 2008-03-19 AR ARP080101150A patent/AR065801A1/es not_active Application Discontinuation
- 2008-03-19 PE PE2008000512A patent/PE20090551A1/es not_active Application Discontinuation
- 2008-03-19 UY UY30974A patent/UY30974A1/es unknown
- 2008-03-20 CL CL200800817A patent/CL2008000817A1/es unknown
- 2008-03-20 TW TW097109757A patent/TW200904414A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11771695B2 (en) | Cannabinoid receptor modulators | |
| CN109641844B (zh) | 整合应激通路的调节剂 | |
| JP6847093B2 (ja) | ムスカリン様アゴニスト | |
| JP6155332B2 (ja) | ピロリジン誘導体、および補体経路調節因子としてのその使用 | |
| CN109863140A (zh) | 3-氧代-2,6-二苯基-2,3-二氢哒嗪-4-甲酰胺 | |
| JP2018534286A5 (enExample) | ||
| KR20150130415A (ko) | 질환의 치료에 유용한 헤테로환식 화합물 | |
| AR062536A1 (es) | Acilanilidas sustituidas y composicion farmaceutica | |
| JP2016513696A5 (enExample) | ||
| CA3129955A1 (en) | Hydroxypyridoxazepines as nrf2 activators | |
| JP6517833B2 (ja) | 神経変性疾患の処置に有用なウィザノライド | |
| CA2931051A1 (en) | Piperidine derivatives having multimodal activity against pain | |
| JP2024160326A (ja) | Ｅａａｔ２活性化因子およびその使用方法 | |
| EA200800975A1 (ru) | ПИРИМИДИНИЛАМИДНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ВКЛЮЧАЮЩАЯ ИХ ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДОВАННОГО α4-ИНТЕГРИНАМИ | |
| US20160068483A1 (en) | Amide derivatives of lactam based n-acylethanolamine acid amidase (naaa) inhibitors | |
| JP2015502371A5 (enExample) | ||
| JP2020525419A (ja) | インドール−ホルムアミド誘導体、その製造方法および薬剤におけるその使用 | |
| JP7247106B2 (ja) | 内臓痛の治療のための化合物および方法 | |
| AU2019295499A1 (en) | Methods and uses of colchicine derivatives | |
| JP2010522181A5 (enExample) | ||
| JP6321274B2 (ja) | トリプル再取込み阻害剤及びそれらの使用方法 | |
| JP2022515869A (ja) | エチレンジアミン化合物及びこれらの使用 | |
| TW200946515A (en) | 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist | |
| JP2019509987A (ja) | Ｅａａｔ３阻害剤としてのピラゾール−ピリジン誘導体 | |
| HUE033615T2 (hu) | Imidazol-karboxamidok, és FAAH inhibitorként történõ alkalmazásuk |